Multiple Cancers: CRC Treatment & Survival Rates
- New research suggests that the sequence in which cancers develop substantially impacts colorectal cancer (CRC) survival rates.
- The study, drawing from the Surveillance, Epidemiology, and End Results (SEER) database, categorized patients into three groups: those with CRC as their only cancer (Group A), those with...
- Anjelli Wignakumar, a clinical research fellow at the Cleveland Clinic in Weston, Florida, noted the unexpected finding.
Discover the surprising impact of cancer sequence on colorectal cancer (CRC) survival. Analysis reveals patients diagnosed with CRC as thier first malignancy experience enhanced survival rates compared to those with subsequent diagnoses or single occurrences. This pivotal research investigated over half a million U.S. patients, offering critical insights into the interplay of primary_keyword and secondary_keyword. Surprisingly, those with CRC as the initial cancer faced a more favorable prognosis. The study highlights the significance of complete screening and early detection strategies for improving survival outcomes particularly within individuals with prior cancers. News Directory 3 provides further facts as well.Discover what’s next in the fight against multiple cancers.
Order of Cancers Plays a Role in Colorectal Cancer Survival
New research suggests that the sequence in which cancers develop substantially impacts colorectal cancer (CRC) survival rates. The study,analyzing data from over half a million U.S. patients, found that individuals diagnosed with CRC as their first malignancy experienced longer survival compared to those who developed it after another primary cancer or as a single occurrence.
The study, drawing from the Surveillance, Epidemiology, and End Results (SEER) database, categorized patients into three groups: those with CRC as their only cancer (Group A), those with CRC as the first of multiple cancers (Group B), and those with CRC as a subsequent cancer (Group C).Surprisingly, Group B demonstrated the highest five-year survival rate.
Dr. Anjelli Wignakumar, a clinical research fellow at the Cleveland Clinic in Weston, Florida, noted the unexpected finding. “We possibly thoght group A would do the best, seeing as they only had one type of cancer. But what we found…is that [group B] actually had the best survival outcome. It could have something to do with the tumor characteristics at a molecular biological level, or potentially as of increased surveillance from having colorectal cancer first,” wignakumar said.
The research also revealed that Group A, while younger, often presented with more aggressive forms of the disease compared to Group C. Right-sided CRC, typically linked to poorer outcomes, was more prevalent in Group C, while left-sided colon cancer, associated with better survival, was more common in Group B.
The study included 592,063 CRC patients from 2000 to 2020, with the majority (71.8%) in Group A, 11.9% in Group B, and 16.3% in Group C. Men comprised a larger proportion of Group B (57.1%). Group A patients were younger at diagnosis (65.7 years) and more likely to have elevated tumor markers and liver or lung metastases.
Surgical intervention was more frequently recommended for Group B (20.5%), while systemic adjuvant therapy was more common in Group A (29.0%). Compared to Group B,Groups A and C showed higher five-year mortality rates,attributed to more advanced disease.
“Patients who develop a second primary cancer have already demonstrated resilience, having endured the physical and emotional challenges of their initial cancer treatment. This experience may reflect a stronger baseline health status and the benefits of previous successful interventions, contributing to potentially better survival outcomes compared with those facing cancer for the first time.”
What’s next
Wignakumar emphasized the importance of comprehensive screening for various cancers, especially CRC, in individuals with a history of primary cancers. tailoring screening strategies based on family history can improve early detection and potentially enhance survival outcomes in patients facing multiple malignancies. The role of cancer sequence and early detection remains critical.